Cardiac CT and MRI. Ashraf Hamdan, MD. Sheba Medical Center. Sheba Medical Center Tel Hashomer. Leviev Heart Center

Similar documents
Cardiac Stress MRI: Detection of Ischemia. Disclosures: Dobutamine Stress MR. April 28, 2018

Disclosures. GETTING TO THE HEART OF THE MATTER WITH MULTIMODALITY CARDIAC IMAGING Organ Review Meeting 25 September. Overview

The role of Magnetic Resonance Imaging in the diagnosis of viability & Coronary Artery Disease

The use of Cardiac CT and MRI in Clinical Practice

Why Cardiac MRI? Presented by:

Imaging Saves Lives: An Evidence-Based Choice of Modality Magnetic Resonance Imaging

Advanced Imaging MRI and CTA

Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users

Cardiac Imaging. Kimberly Delcour, DO, FACC. Mahi Ashwath, MD, FACC, FASE. Director, Cardiac CT. Director, Cardiac MRI

Imaging congestive heart failure: role of coronary computed tomography angiography (CCTA)

MR Assessment of Myocardial Viability

The Value of Stress MRI in Evaluation of Myocardial Ischemia

THE NEW PLACE OF CARDIAC MRI IN AERONAUTICAL FITNESS

Cardiac MRI: Appropriateness. Scott Mattson, DO, FACC Lutheran Medical Group Fort Wayne, IN

Sung A Chang Department of Internal Medicine, Division of Cardiology, Sungkyunkwan University School of Medicine, Samsung Medical Center

Conflict Disclosures. Vermont Cardiac Network. Outline. Series Learning Objectives 4/27/2016. Scott E. Friedman April 28, 2016

ADVANCED CARDIOVASCULAR IMAGING. Medical Knowledge. Goals and Objectives PF EF MF LF Aspirational

Cardiac Imaging Tests

Current Indications for Cardiac MRI: What You See is What You Get?

Detection and Assessment of MI: Use of Imaging Methods. Robert O. Bonow, M.D.

Imaging of the Heart Todd Tessendorf MD FACC

Ve V rmont rmon Card Car iac d Netw Ne ork tw Scott E. Friedman April 28, 2016

I have no financial disclosures

What s New in Cardiac MRI

Imaging in Ischemic Heart Disease: Role of Cardiac MRI

Radiologic Assessment of Myocardial Viability

Imaging and heart failure

CT for Myocardial Characterization of Cardiomyopathy. Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea

Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute

The best from Euro-Echo Ischemic heart disease. Fausto Rigo,FESC Department of Cardiology Mestre-Venezia Hospital,Italy

Chapter 5 Section 1.1. Diagnostic Radiology (Diagnostic Imaging)

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

Acute chest pain: game changer or waste of resources? CMR one stop shop for function, structure and perfusion

MRI ACS-ben. Tamás Simor MD, PhD, Med Hab. University of Pécs, Heart Institute

SPECT-CT: Τι πρέπει να γνωρίζει ο Καρδιολόγος

Perfusion, Viability, Edema and Hemorrhage: How it Can (and Should) Change Clinical Practice. Rohan Dharmakumar, Ph.D.

Cardial MRI; Approaching the Level of Gold Standard for Viability Assessment

Imaging of Coronary Artery Disease: II

Case based learning: CMR in Heart Failure

Chapter 5 Section 1.1

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

Stable Angina: Indication for revascularization and best medical therapy

Rotation: Imaging 2. Nuclear Cardiology (in Imaging 1 and 2)

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Functional aspects of anatomical imaging techniques

9/2/2016 CARDIOLOGY TESTING WHAT TO ORDER WHEN REFERENCE OBJECTIVES

Imaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD

Current Guidelines for Diagnosis of AMI Chest pain ST change on EKG Cardiac Enzymes

Cardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures?

DECLARATION OF CONFLICT OF INTEREST. Grant support: Philips Healthcare Bayer Schering

Current and Future Imaging Trends in Risk Stratification for CAD

J. Schwitter, MD, FESC Section of Cardiology

Qualitative and Quantitative Assessment of Perfusion

CASE from South Korea

Non Invasive Diagnostic Modalities for Coronary Artery Disease. Dr. Amitesh Aggarwal

Radiology of the respiratory/cardiac diseases (part 2)

Debate Should we use FFR? I will say NO.

Epicardial VT Ablation The Cleveland Clinic Experience

Welcome! To submit questions during the presentation: or Text:

Cardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni MD FESC

General Cardiovascular Magnetic Resonance Imaging

Cardiac MR -Complimentary -Competitor -Conqueror?

Computed Tomography of the Coronary Arteries

Detailed Order Request Checklists for Cardiology

Role of CMR in heart failure and cardiomyopathy

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

How to investigate (Cardiac) Chest Pain

Coronary Artery Anomalies from Birth to Adulthood; the Role of CT Coronary Angiography in Sudden Cardiac Death Screening

Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future

Newly Diagnosed Heart Failure patient: When to Order an MRI and Why

Cardiac Conditions in Sport & Exercise. Cardiac Conditions in Sport. USA - Sudden Cardiac Death (SCD) Dr Anita Green. Sudden Cardiac Death

DOWNLOAD PDF MYOCARDIAL CONTRAST TWO DIMENSIONAL ECHOCARDIOGRAPHY (DEVELOPMENTS IN CARDIOVASCULAR MEDICINE)

Cardiac MRI: Clinical Application to Disease

IAEA. Department of Technical Cooperation. And. Nuclear Medicine Section RAS 6/063

4/11/2017. Cardiomyopathy. John Steuter, MD Bryan Heart. Disclosures. No Conflicts. Cardiomyopathy. WHO Classification

Cardiovascular Imaging Stress Echo

Screening for Asymptomatic Coronary Artery Disease: When, How, and Why?

Evaluation of Myocardial Viability: What Have We Learned from STICH? Professor of Medicine David Geffen School of Medicine at UCLA. Heart Failure (HF)

DECLARATION OF CONFLICT OF INTEREST

Cardiac MRI in ACHD What We. ACHD Patients

CARDIAC MRI. Cardiovascular Disease. Cardiovascular Disease. Cardiovascular Disease. Overview

IRM cardiaque en cancérologie: le rôle du radiologue

Gated blood pool ventriculography: Is there still a role in myocardial viability?

Cardiovascular manifestations of HIV

Rational use of imaging for viability evaluation

Myocardial Infarction

2019 Qualified Clinical Data Registry (QCDR) Performance Measures

Takotsubo syndrome. Ευτυχία Σμπαρούνη, FACC, FESC

Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity

Pearls & Pitfalls in nuclear cardiology

EAE Teaching Course. Magnetic Resonance Imaging. Competitive or Complementary? Sofia, Bulgaria, 5-7 April F.E. Rademakers

: A SELECTION OF ARTICLES CARDIAC MR AND CT. JN Dacher, Rouen

21st Annual Contemporary Therapeutic Issues in Cardiovascular Disease

Topic. Updates on Definition of Myocardial Infarction

Cardiac MR Cardiac CT

Covered Indications. Evaluation of chest pain syndrome uninterpretable or equivocal stress test (exercise, perfusion, or stress echo)

Coronary Artery Imaging. Suvipaporn Siripornpitak, MD Inter-hospital Conference : Rajavithi Hospital

ECG in coronary artery disease. By Sura Boonrat Central Chest Institute

Cardiac Risk Factors and Noninvasive Cardiac Diagnosis-ECG, ECHO, et al. Martin C. Burke, DO, FACOI ACOI IM Board Review Course 2018

Transcription:

Cardiac CT and MRI Ashraf Hamdan, MD Sheba Medical Center Sheba Medical Center Tel Hashomer Leviev Heart Center

Spatial resolution Resolution 4x4mm If the object incidentally placed in one pixel high image quality Resolution 4x4mm If the object incidentally placed in more than one pixel larger object with low image quality & low render delineation =partial volume effect

Dual Source CT - Rationale Original Image 50 ms 100 ms 250 ms Ideally, motion-free imaging for coronary arteries requires acquisition time to be around 50 ms but the current temporal resolution of MDCT is: 80-200ms: temporal resolution for DSCT = 83 msec, for 64CT = 160msec

EHJ 2013

Pretest probability Low: < 15% - can be managed without further testing Intermediate: 15-85% - stress testing High: > 85% - risk stratification only EHJ 2013 EHJ 2013

Anatomical assessment of CAD CCTA? EHJ 2013

PPV = TP/(TP + FP) NPV = TN/(TN + FN) Schuetz et al. Systemic Reviews 2013,2:13

Effect of BMI on the image quality BMI = 30 kg/m² BMI = 19 kg/m²

CASE I

CASE I

Case II

Case III

Case IV In 2010: typical chest pain

2006-2013 איתסמיני רץ מרתון מדי פעם גורמי סיכון מאוזנים היטב מעקב שגרתי אקו במאמץ כל 2-3 תקינים שנים

2014- מודאג האם התומכן ב LADפתוח איתסמיני מתכונן למרוץ הר לעמק אקו במאמץ-צניחות במקטע ST שלא היו בעבר ללא הפרעה בתנועתיות הדפנות גורמי סיכון מאוזנים היטב מטופל עם סטטין ומטפורמין, אספירין,פלביקס

Case V RVOT Right cusp RV LV Left cusp

Coronary anomalies: Malignant criteria Intramural course: - Slit like ostium - acute angle - asymmetrically positioned between aorta & PA Running between PA and aorta Intra- vs. extramuscular: when intramuscular less malignant

MRI

10 Top MRI Indication 1. Ventricular volumes and function 2. Viability 3. Stress examinations: perfusion and dobutamine stress MRI 4. Cardiomyopathy, myocarditis and infiltrative disease 5. Tumors and Thrombus 6. Pericardial Diseases 7. Magnetic resonance angiography of the great and peripheral vessels 8. Coronary artery imaging 9. Blood flow quantification for shunt sizing and evaluation of valvular heart disease 10. Congenital disease

Need for further modalities?

Interstudy Reproducibility 200 MRI 200 Echo 180 180 160 160 140 140 120 120 100 100 80 1 2 80 1 2 Mean 1 = 131 Mean 2 = 131 SD = 4.6 Mean 1 = 131 Mean 2 = 131 SD = 18 Bellenger. Pennell. JCMR 2000: 2: 271-8

Sample Size Reduction Grothues et al. Am J cardio, 2002; 90-29

Enddiastolic Endsystolic CMR-AKADEMIE.com Determination of LV- Function with Simpson s method is reference standard

MRI vs. SPECT Spatial resolution MRI ~ 2 x 3 mm SPECT ~ 10 x 10 mm 3-D Imaging No Radiation Wagner A et al. Lancet 2003;9355:

Comparison with Dobutamine Stress Echo (DSE) and MRI (DSMR) DSE DSMR P value Sensitivity 74.3% 86.2% < 0.05 Specificity 69.8% 85.7% < 0.05 Pos. predictive value 81.0% 91.3% < 0.05 Neg. predictive value 61.1% 78.3% < 0.05 Accuracy 72.7% 86.0% < 0.005 Nagel et al. Circulation 1999;99:763-770

MRI for the Diagnosis of Coronary Artery Disease Detection of ischemia MRI coronary angiography Perfusion measurements Wall motion analysis

Monitoring & Safety Aspects Continuous monitoring of rhythm/heart rate (vector-ecg) blood pressure respiratory control D Physician and Technician must bei experienced in advanced cardiac life support periodically practice rapid patient evacuation (2 staff members, <30 sec)

Safety of DSMR Side Effects Safety profiles of DSE and DSMR are virtually identical Wahl et al. Eur Heart J 2004

DSMR inducible WMA male, 52 yrs known CAD post multiple interventions of LCX at presentation chest pain, not strictly related to exercise Echo: moderate image quality (esp. endocardial border definition of lateral wall)

4-chamber view rest 20 g 40 g

Endsystole Enddiastole DSMR-02 rest 10µg 20µg max

DSMR-03 inducible, ischemic WMA

Late Enhancement Patterns for Ischemic and Nonischemic Disorders Mahrhold EHJ 26:1461

Mechanism of delayed enhancement Normal myocardium Contrast agent molecules (Gadolinium-chelates) extracellular can not cross cell membrane low concentration Myocardial infarct Membrane rupture Gadolinium-chelates Intracellular Increased concentration hyperenhancement Chronic infarct Myocytes replaced by Collagen large interstitial space Increased concentration hyperenhancement intact cell membrane ruptured cell membrane Collagen matrix

Case I Male, 17 yrs Medical history: Smoker 7-days history of Fever 38.9, Sore throat, weakness At presentation: acute chest pain and dyspnea Laboratory workup: Troponin-I positive = (33 micg/l); CPK = 1630 IU/L

Invasive Angiogram

Acute myocarditis 5-months later

Acute myocarditis 5-months later

Acute myocarditis 5-months later

Case II: Gaint cell myocarditis Signal Intensity measurement Myocardium: 164g Scar: 54g, 33% Edema: 68g, 40%

Case II ischaemic vs. Non-ischaemic CMP

Acute MI 3 weeks later

Case III Male, 56 yrs Medical history: s/p inferior MI (s/p PCI to RCA), Smoker 3-days history of Fever and chest pain Laboratory workup: Troponin-I positive = (25 micg/l); CRP = 190

Case IV

Apical 82% Multicenter study in 207 pts. Midventricular 82% Basal 82% Possible etiology - Inflammation - increased LV wall stress - transient ischemia - myocardial edema Biventricular 34% Eitel et al. JAMA 2011; 306:277

Preceding stressful events

Case VI Female, 51 yrs Medical history: Smoker, positive family history for CAD At presentation: Non specific chest pain Laboratory workup: Troponin-I positive = (18.9 micg/l); CPK = 785 IU/L

Invasive Angiogram

MRI

ARVD

Case V Male, 44y Syncope

Sarcoidosis

Sarcoma Black blood DE Broad based & large mass - Heterogeneous enhancement corresponding to Necrosis - The most common cardiac malignant tumor Isointense in T1 -The majority of occur in the right atrium - Mean survival 3 months to 1 year TGE without contrast TGE with contrast

Lipoma Without fat suppression With fat suppression

Lipoma Delayed enhancement Perfusion

Lipoma

Lipoma

Thrombus 5 days after MVR

Pericarditis

Non compaction